Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Development and testing of advanced delivery strategies, such as nanoformulations and prodrugs, are needed to overcome bioavailability challenges and improve central nervous system penetration and target engagement
That triggers a prior authorization request for the Bridge program, which the provider must complete to certify that the individual is eligible
doi: 10.1111/jdi.12463
Nature 598 , 662666 (2021)
Clinical Effectiveness: SURMOUNT-1 Trial (Tirzepatide 15 mg): Duration: 72 weeks Participants: 2,539 adults with obesity Average Weight Loss: 22.5% of body weight 10 mg Dose: 21.4% weight loss 5 mg Dose: 15.0% weight loss Placebo: 2.4% weight loss 5% Weight Loss: 96% of participants 10% Weight Loss: 89% of participants 15% Weight Loss: 78% of participants 20% Weight Loss: 63% of participants This is the best weight loss result ever achieved with medication in clinical trials
US$ 26.74
US$ 24.26
US$ 23.73
